Will AI Play a Large Role for Edwards in 2019?

Artificial intelligence could play a much bigger role in boosting Edwards Lifesciences' revenues going forward. During its most recent earnings call, the Irvine, CA-based company's CEO said its software for the HemoSphere should be significant growth driver this year. HemoSphere is a monitor that gives insight on a patient's physiologic status and can analyze trends. Late last year, the company received a nod from FDA for Acumen Hypotension Prediction Index, a software that adds an AI component to the platform. "This platform is designed to provide greater clarity on a patient's hemodynamic status and enables our AI capabilities," Edwards Lifesciences CEO Michael Mussallem, said according to a Seeking Alpha Transcript.